Download PDF
Thromb Haemost 1966; 16(01/02): 228-242
DOI: 10.1055/s-0038-1655640
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Studies on Experimentally Induced Hypercoagulable State in Rabbits

G Izak M. D.
1   Hematology Research Laboratory and the Department of Medicine B, The Hebrew University-Hadassah Medical School and the Hadassah University Hospital, Jerusalem, Israel
,
K Galewsky
1   Hematology Research Laboratory and the Department of Medicine B, The Hebrew University-Hadassah Medical School and the Hadassah University Hospital, Jerusalem, Israel
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

The theory of the dynamic equilibrium in vivo between the opposing functions of the coagulation and fibrinolytic mechanisms was tested in rabbits with artificially induced hyper- and hypocoagulable states.

When repeated estimations of the various clotting and fibrinolytic constituents were performed simultaneously with the determination of the disappearance rate of I131 labeled fibrinogen, thromboplastin induced hypercoagulable state could be monitored. Measuring the same parameters, interference with the coagulation system by the use of anticoagulants was found ineffective concerning the coagulation and fibrinolytic systems. Furthermore, the latter procedures were unable to modify the pattern of changes when employed in animals with artificially induced hypercoagulable state.

The data presented militate strongly against the dynamic equilibrium hypothesis as suggested by several investigators.

 

  • References

  • 1 Biggs R, Douglas A. S, Macfariane R. G. The initial stages of blood coagulation. J. Physiol 122: 538 1953;
    CrossrefPubMedGoogle Scholar
  • 2 Biggs R, Macfariane R. G. In: Human blood coagulation. 139 Blackwell Scientific Publications; Oxford: 1962
    Google Scholar
  • 3 Astrup T. The biological significance of fibrinolysis. Lancet. 565 1956
    PubMedGoogle Scholar
  • 4 Copley A. L. Neue Auffassungen über Haemorrhagie, Haemostase und Thrombose. Ärztl. Forsch 11: 114 1957;
    PubMedGoogle Scholar
  • 5 Fearnley G. R. A concept of natural fibrinolysis. Lancet I: 992 1961;
    PubMedGoogle Scholar
  • 6 Fearnley G. R. In: Fibrinolysis. 145-146 Edward Arnold Ltd.; 1965. London:
    Google Scholar
  • 7 Christensen L. R. Proc. 6th Cong. Europ. Soc. Hemat. 429 Karger; Basel: 1957
    Google Scholar
  • 8 Verstraete M, Amery A, Vermylen Y, Vermylen C, DeVrecker R. Practical method for thrombolytic therapy with Streptokinase. Brit. med. J 1: 675 1964;
    CrossrefPubMedGoogle Scholar
  • 9 Gajewski Y, Alexander B. Effect of epsilonaminocaproic acid on the turnover of labeled fibrinogen in rabbits. Circ. Res 13: 432 1963;
    CrossrefPubMedGoogle Scholar
  • 10 Lee R. I, Withe P. D. A clinical study of the coagulation time of blood. Amer. J. med. Sci 35: 964 1913;
    PubMedGoogle Scholar
  • 11 Budtz-Olsen O. E. Clot retraction. Blackwell Scientific Publications; Oxford: 1951
    Google Scholar
  • 12 Ratnoff O. D, Menzie C. A new method for determination of fibrinogen in small samples of plasma. J. Lab. clin. Med 37: 316 1951;
    PubMedGoogle Scholar
  • 13 Quick A. J. Determination of prothrombin. In: Quick A. J. The physiology and pathology of hemostasis. 125 Lea &Fabiger; 1951. Philadelphia:
    Google Scholar
  • 14 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path 19: 471 1949;
    PubMedGoogle Scholar
  • 15 Stefanini M. New one-stage procedures for the quantitative determination of prothrombin and labile factor. Amer. J. clin. Path 20: 233 1950;
    PubMedGoogle Scholar
  • 16 Alexander B. Clotting factor VII (Proconvertin): Synonymy, properties clinical and clinico-laboratory aspects. New Engl. J. Med 260: 1218 1959;
    CrossrefPubMedGoogle Scholar
  • 17 Wright I. S, Koller F, Streuli F. New blood clotting factors. Thrombos. Diathes. haemorrh. (Suppl.) 4: 1 1960;
    PubMedGoogle Scholar
  • 18 Von Kaulla K. N, Schultz R. L. Methods for the evaluation of human fibrinolysis. Amer. J. clin. Path 29: 104 1958;
    PubMedGoogle Scholar
  • 19 Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path 6: 23 1953;
    CrossrefPubMedGoogle Scholar
  • 20 Ebough F. G, Emerson C. P, Ross J. F. The use of radioactive Cr51 as an erythrocyte tagging agent for the determination of red cell survival in vivo. J. clin. Invest 32: 1260 1953;
    CrossrefPubMedGoogle Scholar
  • 21 Blombäck B. Studies on fibrinogen: its purification and conversion into fibrin. Acta-physiol. scand. (Suppl. 148) 43: 7 1958;
    CrossrefPubMedGoogle Scholar
  • 22 Iodination of Proteins. Studies with marked antisera. Boursnell, Coombs and V. Rizk. Biochem. J 55: 745 1953;
    PubMedGoogle Scholar
  • 23 Hecht E. R, Cho M. H, Seegers W. H. Thromboplastin: Nomenclature and preparation of protein-free material different from platelet factor 3 or liquid activator. Amer. J. Physiol 193: 584 1958;
    PubMedGoogle Scholar
  • 24 Zetterquist E, Blombäck B, Carlson L. A, Franzen S. The turnover of I131 labeled fibrinogen in man. Xth Cong. Int. Soc. Haemat. Stockholm, Ljunghofs Litografiska A. B. 1964, p. G: 77
    PubMedGoogle Scholar
  • 25 Izak G, Galewski K, Eyal Z. Hypercoagulable state. Proc. IIId Cong. Asian Pacific Soc. Hemat., Isr. J. med. Sci. 1:Suppl., 1965 (In press.)
    PubMedGoogle Scholar
  • 26 Roos J. Blood coagulation as a continuous process. Thrombos. Diathes. haemorrh (Stuttg.) i: 471 1957;
    PubMedGoogle Scholar
  • 27 Klein P. D, Seegers W. H. The nature of plasma antithrombin activity. Blood 5: 742 1950;
    PubMedGoogle Scholar
  • 28 Pechet L, Alexander B. The effect of certain proteolytic enzymes on thrombin fibrinogen interaction. Biochem. J 1: 875 1962;
    CrossrefPubMedGoogle Scholar